Finally, good news has come against our fight with COVID-19! In India, Glenmark has received the regulatory approval for oral antiviral Favipiravir to treat COVID-19 affected patients. Glenmark is the first pharmaceutical firm in the country that has manufacturing and marketing support for an oral drug with brand name FabiFlu to treat COVID-19 patients from mild to moderate symptoms.
About Glenmark Fabiflu COVID 19 Medicine:
The patients with mild to moderate COVID symptoms benefit from the use of Glenmark Fabiflu COVID 19 medicine. The drug will be available to the needy patients for Rs 103 for 200 mg tablet and at an MRP of Rs 3500 for a strip of 34 tablets. The patients recommend to consume 1800 mg twice a day from day 1, and 800 mg regularly used upto day 14. The drug will remain available both at the hospitals and at the retail stores.
As per Glenmark, this drug shows 88% clinical improvements with a rapid reduction in viral load by four days. Clinical results have proved the effectiveness of the drug for the patients with age groups from 20 to 90 years, also who are suffering from diabetes and heart diseases.
Favipiravir is an oral product with a wide therapeutic safety margin and has already been approved for a new pandemic influenza virus infection in Japan since 2014.
Glenmark, the patients should start consuming the drug early, considering the severity of the disease. In the later stages of the disease, viral replication gets slow down, and the human body’s violent immune response drives disease, which leads to many complications and even organ failure?
Contraindications to the drug:
Favipiravir used by patients with severe renal, hepatic impairment, and pregnancy.
Patients should avoid using this drug with a history of hypersensitivity to Favipiravir. Patients should avoid using this drug with a history of hypersensitivity to Favipiravir.
A combination of Favipiravir and Umifenovir:
The company has recommended the combined use of Favipiravir and Umifenovir as an antiviral drug of the SARS-Cov-2 virus. To be more specific, Favipiravir is the approved drug for novel flu pandemics, while Umifenovir is the recommended drug for Influenza.
About Glenmark Pharmaceuticals Ltd:
With headquarters in Mumbai, Glenmark is a leading research-based pharmaceutical company founded in 1977 by Gracias Saldanha. In terms of generating revenue, the company has scored the 80th among the Pharma & Biotech companies globally.
With 50 local offices, 15 manufacturing facilities, and 3 Research & development centers, the company goal is to make human lives better.
On June 19, the company received approval for India’s first COVID 19 drug from Drugs Controller General of India (DCGI).
At present, the company’s focus is on manufacturing intending to make FabiFlu accessible to all needy patients. If everything goes well, Glenmark is supporting the private and public healthcare facilities and proposing other suitable options.